Replaces Prod. #: BML-CN221
ODQ is a potent and selective, direct-acting inhibitor of guanylate cyclase (IC50=20 nM). In cerebellar slices ODQ reversibly inhibited cGMP generation in response to endogenous NO or exogenously added NO-donors. ODQ does not inhibit NO-mediated macrophage toxicity (a phenomenon unrelated to cGMP) and does not inhibit particulate guanylyl cyclase or adenylyl cyclase. ODQ is an unique and selective tool to elucidate the physiological importance of the NO-cGMP pathway.
Product Details
Formula: | C9H5N3O2 |
|
MW: | 187.2 |
|
CAS: | 41443-28-1 |
|
Purity: | ≥98% (TLC) |
|
Appearance: | Off-white to yellow powder. |
|
Solubility: | Soluble in DMSO (5mg/ml), ethyl acetate or 100% ethanol (1.2mg/ml); insoluble in water. |
|
Shipping: | Ambient Temperature |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Solutions may decompose slowly. |
|
Handling: | Protect from light. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Novel analgesic/anti-inflammatory agents: 1,5-Diarylpyrrole nitrooxyethyl sulfides and related compounds as Cyclooxygenase-2 inhibitors containing a nitric oxide donor moiety endowed with vasorelaxant properties: M. Saletti, et al.; Eur. J. Med. Chem.
241, 114615 (2022),
Abstract;
Fermented garlic extract decreases blood pressure through nitrite and sGC-cGMP-PKG pathway in spontaneously hypertensive rats: B.M. Park, et al.; J. Funct. Foods 22, 156 (2016), Application(s): Cell culture,
Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice: E.P. Schmidt, et al.; Am. J. Physiol. Lung Cell. Mol. Physiol.
295, (2008),
Abstract;
Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols: R. Motterlini, et al.; J. Biol. Chem.
275, 13613 (2000),
Abstract;
Full Text
Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea: T.L. Hwang, et al.; Br. J. Pharmacol.
125, 1158 (1998),
Abstract;
A comparative study of the effects of three guanylyl cyclase inhibitors on the L-type Ca2+ and muscarinic K+ currents in frog cardiac myocytes: N. Abi-Gerges, et al.; Br. J. Pharmacol.
121, 1369 (1997),
Abstract;
Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles: C.G. Sobey & F.M. Faraci; Stroke
28, 837 (1997),
Abstract;
Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation: L.J. Olson, et al.; Hypertension
29, 254 (1997),
Abstract;
cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase: M.A. Moro, et al.; PNAS
93, 1480 (1996),
Abstract;
Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase: A. Schrammel, et al.; Mol. Pharmacol.
50, 1 (1996),
Abstract;
The nitric oxide-cyclic GMP pathway and synaptic plasticity in the rat superior cervical ganglion: E. Southam, et al.; Br. J. Pharmacol.
119, 527 (1996),
Abstract;
Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase: C.L. Boulton, et al.; Neuroscience
69, 699 (1995),
Abstract;
Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion: F. Brunner, et al.; FEBS Lett.
376, 262 (1995),
Abstract;
Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one: J. Garthwaite, et al.; Mol. Pharmacol.
48, 184 (1995),
Abstract;
General Literature References
Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase: S. Cellek, et al.; Br. J. Pharmacol.
118, 137 (1996),
Abstract;
Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery: F. Brunner, et al.; J. Pharmacol. Exp. Ther.
277, 48 (1996),
Abstract;